JY
ARTV

Jeff Yass’s Artiva Biotherapeutics ARTV Stock Holding History

Jeff Yass’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,121
Closed -$24.3K – 14176
2025
Q2 		$24.3K Sell
16,121
-8,236
-34% -$17.3K ﹤0.01% 12291
2025
Q1 		$73.1K Buy
+24,357
New +$131K ﹤0.01% 11723

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jeff Yass's ARTV Position: Q3 2025 in Review

Jeff Yass sold out of Artiva Biotherapeutics (ARTV) in Q3 2025, closing a stake of 16,121 shares — an estimated $24.3K sold.

Jeff Yass first reported a position in ARTV in Q1 2025 and held it in 2 quarters. The position peaked at $73.1K in Q1 2025. 40 funds tracked by Wall St. Rank hold ARTV as of Q3 2025.

  • Jeff Yass reported no remaining Artiva Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Jeff Yass sold 16,121 Artiva Biotherapeutics shares in Q3 2025, an estimated $24.3K.
  • Jeff Yass first reported a position in Artiva Biotherapeutics in Q1 2025 and held it in 2 quarters.
  • Jeff Yass's Artiva Biotherapeutics position peaked at $73.1K in Q1 2025.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.